Piramal Pharma Limited (NSE:PPLPHARMA)
India
· Delayed Price · Currency is INR 151.87
-1.43 (-0.93%)
At close: Mar 6, 2026
Piramal Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Operating Revenue | 88,714 | 91,512 | 81,712 | 70,816 | 65,591 | 58,291 |
| Other Revenue | - | - | - | - | 1,750 | 576.37 |
| Revenue | 88,714 | 91,512 | 81,712 | 70,816 | 67,341 | 58,868 |
| Revenue Growth (YoY) | -0.87% | 11.99% | 15.39% | 5.16% | 14.39% | - |
| Cost of Revenue | 34,613 | 35,551 | 32,617 | 29,713 | 24,512 | 20,736 |
| Gross Profit | 54,101 | 55,961 | 49,095 | 41,103 | 42,829 | 38,132 |
| Selling, General & Admin | 26,516 | 25,171 | 22,034 | 21,046 | 15,888 | 14,761 |
| Other Operating Expenses | 17,322 | 16,299 | 15,054 | 13,736 | 15,477 | 9,508 |
| Operating Expenses | 52,393 | 49,633 | 44,493 | 41,549 | 37,227 | 29,301 |
| Operating Income | 1,708 | 6,328 | 4,601 | -446.5 | 5,602 | 8,831 |
| Interest Expense | -3,578 | -4,179 | -4,470 | -3,377 | -1,888 | -1,459 |
| Interest & Investment Income | 105.8 | 105.8 | 119.2 | 16.4 | 6.8 | 37.11 |
| Earnings From Equity Investments | 598.4 | 729.3 | 594.9 | 543.3 | 590.3 | 436.06 |
| Currency Exchange Gain (Loss) | 380.9 | 380.9 | 304 | 1,108 | 168.6 | 565.57 |
| Other Non Operating Income (Expenses) | 1,239 | 494.5 | 762.6 | 523.3 | -94.7 | -50.12 |
| EBT Excluding Unusual Items | 453.6 | 3,859 | 1,912 | -1,633 | 4,385 | 8,361 |
| Merger & Restructuring Charges | - | - | - | -69.6 | -150.8 | -416.77 |
| Gain (Loss) on Sale of Investments | 90.5 | 90.5 | 43.5 | 15.8 | 19.5 | - |
| Gain (Loss) on Sale of Assets | 14.4 | 14.4 | -4.6 | -4.8 | -5.4 | 10.52 |
| Asset Writedown | - | - | - | - | - | -377.08 |
| Other Unusual Items | -21.1 | 182.6 | -158.4 | 490 | 601.3 | 1,183 |
| Pretax Income | 537.4 | 4,146 | 1,793 | -1,202 | 4,850 | 8,760 |
| Income Tax Expense | 2,174 | 3,235 | 1,615 | 663.1 | 1,090 | 1,052 |
| Net Income | -1,636 | 911.3 | 178.2 | -1,865 | 3,760 | 7,708 |
| Net Income to Common | -1,636 | 911.3 | 178.2 | -1,865 | 3,760 | 7,708 |
| Net Income Growth | - | 411.39% | - | - | -51.23% | - |
| Shares Outstanding (Basic) | 1,323 | 1,323 | 1,281 | 1,190 | 1,179 | 628 |
| Shares Outstanding (Diluted) | 1,323 | 1,331 | 1,284 | 1,190 | 1,179 | 628 |
| Shares Change (YoY) | -0.55% | 3.67% | 7.85% | 0.95% | 87.83% | - |
| EPS (Basic) | -1.24 | 0.69 | 0.14 | -1.57 | 3.19 | 12.28 |
| EPS (Diluted) | -1.24 | 0.68 | 0.14 | -1.57 | 3.19 | 12.28 |
| EPS Growth | - | 388.86% | - | - | -74.02% | - |
| Free Cash Flow | - | 2,279 | 2,925 | -4,809 | -1,231 | -42.55 |
| Free Cash Flow Per Share | - | 1.71 | 2.28 | -4.04 | -1.04 | -0.07 |
| Dividend Per Share | - | 0.140 | 0.110 | - | 0.980 | - |
| Dividend Growth | - | 27.27% | - | - | - | - |
| Gross Margin | 60.98% | 61.15% | 60.08% | 58.04% | 63.60% | 64.78% |
| Operating Margin | 1.93% | 6.92% | 5.63% | -0.63% | 8.32% | 15.00% |
| Profit Margin | -1.84% | 1.00% | 0.22% | -2.63% | 5.58% | 13.09% |
| Free Cash Flow Margin | - | 2.49% | 3.58% | -6.79% | -1.83% | -0.07% |
| EBITDA | 9,543 | 13,715 | 11,391 | 5,764 | 11,099 | 12,970 |
| EBITDA Margin | 10.76% | 14.99% | 13.94% | 8.14% | 16.48% | 22.03% |
| D&A For EBITDA | 7,835 | 7,387 | 6,790 | 6,211 | 5,497 | 4,139 |
| EBIT | 1,708 | 6,328 | 4,601 | -446.5 | 5,602 | 8,831 |
| EBIT Margin | 1.93% | 6.92% | 5.63% | -0.63% | 8.32% | 15.00% |
| Effective Tax Rate | 404.45% | 78.02% | 90.06% | - | 22.48% | 12.01% |
| Revenue as Reported | 90,807 | 92,860 | 83,466 | 73,067 | 68,349 | 59,806 |
| Advertising Expenses | - | 1,767 | 1,423 | 1,762 | 1,513 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.